Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients Treated With Tolvaptan

Spithoven, 2014, Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry, Nephrol Dial Transplant, 29, iv15, 10.1093/ndt/gfu017 Chapman, 2015, Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference, Kidney Int, 88, 17, 10.1038/ki.2015.59 Suwabe, 2013, Quality of life of patients with ADPKD-Toranomon PKD QOL study: cross-sectional study, BMC Nephrol, 14, 179, 10.1186/1471-2369-14-179 Simms, 2016, Increased psychosocial risk, depression and reduced quality of life living with autosomal dominant polycystic kidney disease, Nephrol Dial Transplant, 31, 1130, 10.1093/ndt/gfv299 Rizk, 2009, Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis, Clin J Am Soc Nephrol, 4, 560, 10.2215/CJN.02410508 Miskulin, 2014, Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study, Am J Kidney Dis, 63, 214, 10.1053/j.ajkd.2013.08.017 Eriksson, 2017, Health-related quality of life across all stages of autosomal dominant polycystic kidney disease, Nephrol Dial Transplant, 32, 2106 Neijenhuis, 2017, The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression, BMC Nephrol, 18, 169, 10.1186/s12882-017-0578-6 Neijenhuis, 2015, Somatostatin analogues improve health-related quality of life in polycystic liver disease: a pooled analysis of two randomised, placebo-controlled trials, Aliment Pharmacol Ther, 42, 591, 10.1111/apt.13301 Torres, 2012, Tolvaptan in patients with autosomal dominant polycystic kidney disease, N Engl J Med, 367, 2407, 10.1056/NEJMoa1205511 Torres, 2017, Tolvaptan in later-stage autosomal dominant polycystic kidney disease, N Engl J Med, 377, 1930, 10.1056/NEJMoa1710030 Chebib, 2018, A practical guide for treatment of rapidly progressive ADPKD with tolvaptan, J Am Soc Nephrol, 29, 2458, 10.1681/ASN.2018060590 Pei, 2009, Unified criteria for ultrasonographic diagnosis of ADPKD, J Am Soc Nephrol, 20, 205, 10.1681/ASN.2008050507 Cornec-Le Gall, 2016, The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease, J Am Soc Nephrol, 27, 942, 10.1681/ASN.2015010016 Irazabal, 2015, Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials, J Am Soc Nephrol, 26, 160, 10.1681/ASN.2013101138 Levey, 2009, A new equation to estimate glomerular filtration rate, Ann Intern Med, 150, 604, 10.7326/0003-4819-150-9-200905050-00006 Kallich, 1995, The RAND Kidney Disease and Quality of Life instrument, Nephrol News Issues, 9, 29 Roser, 2019, Health-related quality of life in Switzerland: normative data for the SF-36v2 questionnaire, Qual Life Res, 28, 1963, 10.1007/s11136-019-02161-5 Ware, 2000, SF-36 health survey update, Spine (Phila Pa 1976), 25, 3130, 10.1097/00007632-200012150-00008 Ware, 1992, The MOS 36-Item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection, Med Care, 30, 473, 10.1097/00005650-199206000-00002 Ware, 1998, Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project, J Clin Epidemiol, 51, 903, 10.1016/S0895-4356(98)00081-X Hays, 1994, Development of the Kidney Disease Quality of Life (KDQOL) instrument, Qual Life Res, 3, 329, 10.1007/BF00451725 Mujais, 2009, Health-related quality of life in CKD patients: correlates and evolution over time, Clin J Am Soc Nephrol, 4, 1293, 10.2215/CJN.05541008 McKercher, 2013, Psychosocial factors in adults with chronic kidney disease: characteristics of pilot participants in the Tasmanian Chronic Kidney Disease study, BMC Nephrol, 14, 83, 10.1186/1471-2369-14-83 Vickers, 2001, Statistics notes: analysing controlled trials with baseline and follow up measurements, BMJ, 323, 1123, 10.1136/bmj.323.7321.1123 2015 Jann, 2014, Plotting regression coefficients and other estimates, Stata J, 14, 708, 10.1177/1536867X1401400402 Lee, 2003, Laparoscopic cyst decortication in autosomal dominant polycystic kidney disease: impact on pain, hypertension, and renal function, J Endourol, 17, 345, 10.1089/089277903767923100 Temmerman, 2014, Development and validation of a polycystic liver disease complaint-specific assessment (POLCA), J Hepatol, 61, 1143, 10.1016/j.jhep.2014.06.024 van Keimpema, 2009, Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial, Gastroenterology, 137, 1661, 10.1053/j.gastro.2009.07.052 de Barros, 2011, Anxiety, depression, and quality of life in patients with familial glomerulonephritis or autosomal dominant polycystic kidney disease, J Bras Nefrol, 33, 120 Hogan, 2010, Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease, J Am Soc Nephrol, 21, 1052, 10.1681/ASN.2009121291 Oberdhan, 2018, Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: a new health-related quality-of-life instrument, Am J Kidney Dis, 71, 225, 10.1053/j.ajkd.2017.08.020